Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.56 |
| ▸ | ITGAV | P06756 | 15/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.56 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716846 | 0.91 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4720020 | 0.90 | ITGB3 (0.46) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4718116 | 0.89 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4718124 | 0.84 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4718667 | 0.82 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4718120 | 0.82 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4715705 | 0.81 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4762284 | 0.78 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4762157 | 0.78 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL4760017 | 0.77 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | claimed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |